Protein Microarray Analysis of Disease Activity in Pediatric Inflammatory Bowel Disease Demonstrates Elevated Serum PLGF, IL-7, TGF-beta1, and IL-12p40 Levels in Crohn's Disease and Ulcerative Colitis Patients in Remission versus Active Disease

Kader, Howard A.; Tchernev, Velizar T.; Satyaraj, Ebenezer; Lejnine, Serguei; Kotler, Gregory; Kingsmore, Stephen F.; Patel, Dhavalkumar D.

doi:10.1111/j.1572-0241.2005.40819.x

Cited by 102 publications

(88 citation statements)

References 59 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TGFb1 is very probably implicated in organ fibrosis, and may be overexpressed by CD stricture fibroblasts. Tissue levels of this cytokine are transiently diminished in the early phases of IBD, whereas they increase at later disease stages (33,110). It has been hypothesized that the TGFb1 cell signaling pathway is defective in IBD: Up-regulation of Smad7, the intracellular inhibitory molecule of the TGFb1 signal, followed by a block of FIG.…”

Section: B Cytokines Produced By T-regulatory Cellsmentioning

confidence: 99%

Inflammatory Bowel Disease: Mechanisms, Redox Considerations, and Therapeutic Targets

Biasi

Leonarduzzi

Oteiza

et al. 2013

Antioxidants & Redox Signaling

211

127

View full text Add to dashboard Cite

Oxidative stress is thought to play a key role in the development of intestinal damage in inflammatory bowel disease (IBD), because of its primary involvement in intestinal cells' aberrant immune and inflammatory responses to dietary antigens and to the commensal bacteria. During the active disease phase, activated leukocytes generate not only a wide spectrum of pro-inflammatory cytokines, but also excess oxidative reactions, which markedly alter the redox equilibrium within the gut mucosa, and maintain inflammation by inducing redoxsensitive signaling pathways and transcription factors. Moreover, several inflammatory molecules generate further oxidation products, leading to a self-sustaining and auto-amplifying vicious circle, which eventually impairs the gut barrier. The current treatment of IBD consists of long-term conventional anti-inflammatory therapy and often leads to drug refractoriness or intolerance, limiting patients' quality of life. Immune modulators or anti-tumor necrosis factor a antibodies have recently been used, but all carry the risk of significant side effects and a poor treatment response. Recent developments in molecular medicine point to the possibility of treating the oxidative stress associated with IBD, by designing a proper supplementation of specific lipids to induce local production of anti-inflammatory derivatives, as well as by developing biological therapies that target selective molecules (i.e., nuclear factor-jB, NADPH oxidase, prohibitins, or inflammasomes) involved in redox signaling. The clinical significance of oxidative stress in IBD is now becoming clear, and may soon lead to important new therapeutic options to lessen intestinal damage in this disease.

show abstract

Section: B Cytokines Produced By T-regulatory Cellsmentioning

confidence: 99%

Inflammatory Bowel Disease: Mechanisms, Redox Considerations, and Therapeutic Targets

Biasi

Leonarduzzi

Oteiza

et al. 2013

Antioxidants & Redox Signaling

211

127

View full text Add to dashboard Cite

show abstract

“…In the sandwich assays such as cytokine and ELISA arrays, proteins captured on an antibody microarray are detected by a cocktail of detection antibodies, each antibody matched to one of the spotted antibodies. These sandwich-based arrays are extremely sensitive for low abundant cytokines or growth factors [112][113][114][115]. The correct use and interpretation of antibody microarray data requires proper normalization of the data.…”

Section: Protein Arraysmentioning

confidence: 99%

Human body fluid proteome analysis

2006

View full text Add to dashboard Cite

The focus of this article is to review the recent advances in proteome analysis of human body fluids, including plasma/serum, urine, cerebrospinal fluid, saliva, bronchoalveolar lavage fluid, synovial fluid, nipple aspirate fluid, tear fluid, and amniotic fluid, as well as its applications to human disease biomarker discovery. We aim to summarize the proteomics technologies currently used for global identification and quantification of body fluid proteins, and elaborate the putative biomarkers discovered for a variety of human diseases through human body fluid proteome (HBFP) analysis. Some critical concerns and perspectives in this emerging field are also discussed. With the advances made in proteomics technologies, the impact of HBFP analysis in the search for clinically relevant disease biomarkers would be realized in the future.

show abstract

“…В зависимости от цели использования биочипы можно разделить на аналитические и функциональные. Анали-тические служат для выявления белковых профилей в биологических жидкостях и тканях; функциональные используются для изучения биохимических особенно-стей протеома [15,18,19]. Аналитическая чувствитель-ность биочипов примерно в 2 раза выше, чем при имму-нофлюоресцентном и иммуноферментном анализе (ИФА) [20].…”

Section: белковые микрочипы (биочипы)unclassified